1.Antrafenine: anti-inflammatory activity with respect to oedema and leucocyte infiltration in the rat.
Dunn CJ, Prouteau M, Delahaye M, Purcell T, Branceni D. Agents Actions. 1984 Feb;14(2):296-9.
Antrafenine effectively suppressed carrageenan paw oedema in the rat (ED 40 = 24 mg/kg p.o) in the dose range of 10-40 mg/kg p.o, approximating that of phenylbutazone. Antrafenine was superior to phenylbutazone with respect to inhibition of exudate volume and total leucocyte infiltration in carrageenan and calcium pyrophosphate dihydrate crystal pleurisies. The effect of antrafenine on leucocytes was most striking, significant suppression being observed at each dose tested (10, 20, 40 mg/kg p.o), whereas phenylbutazone showed significant activity only at the relatively elevated dose of 40 mg/kg p.o. These observations suggest that antrafenine merits further investigation with respect to its anti-inflammatory effects.
2.In-vivo metabolism in the rat and mouse of antrafenine to 1-m-trifluoromethylphenylpiperazine.
Caccia S, Conti I, Notarnicola A. J Pharm Pharmacol. 1985 Jan;37(1):75-7.
The analgesic antrafenine forms 1-m-trifluoromethylphenylpiperazine (mCF3PP) during its biotransformation in the rat and mouse. At least 14 and 3% of an antrafenine dose (25 mg kg-1 p.o.) reaches the systemic circulation as mCF3PP in the mouse and rat respectively. The metabolite easily enters the brain, reaching concentrations several times those in body fluids. This, together with the fact that mCF3PP is known to produce several pharmacological effects compatible with a stimulatory action on 5-hydroxytryptamine postsynaptic receptors, suggests that this metabolite may contribute to the parent drug's pharmacological effects.